(ESPR) Esperion Therapeutics - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 803m USD | Total Return: 259.5% in 12m
Avg Turnover: 26.9M
Qual. Beats: 0
Rev. Trend: 88.1%
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
Share dilution 28.2% YoY
Altman Z'' -10.30 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Esperion Therapeutics, Inc. is a biopharmaceutical firm focused on the development and commercialization of oral, non-statin therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Its primary product portfolio includes NEXLETOL and NEXLIZET, which utilize bempedoic acid to inhibit ATP Citrate Lyase (ACL), thereby reducing cholesterol biosynthesis and up-regulating LDL receptors. The company operates within the biotechnology sector, where high research and development costs often lead to strategic licensing and collaboration agreements to manage global distribution and regulatory hurdles.
The company expanded its market reach through significant partnerships with international pharmaceutical entities such as Daiichi Sankyo and Otsuka Pharmaceutical. This business model leverages external commercial infrastructure to scale the adoption of its cardiovascular treatments in Europe and Asia. For a deeper look into the companys valuation metrics and growth potential, explore the data on ValueRay. Headquartered in Michigan, Esperion remains a specialized player in the lipid-management market, targeting adult patients with heterozygous familial hypercholesterolemia or established cardiovascular disease.
- FDA label expansion drives increased adoption of NEXLETOL for cardiovascular risk reduction
- Daiichi Sankyo milestone payments and royalty streams provide essential non-dilutive capital
- Market penetration of non-statin therapies competes directly with low-cost generic alternatives
- Managed care coverage and patient access programs dictate domestic NEXLIZET revenue growth
- Research and development expenses for pipeline expansion impact long-term cash runway sustainability
| Net Income: -7.42m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA 27.04 > 1.0 |
| NWC/Revenue: 38.04% < 20% (prev 18.42%; Δ 19.62% < -1%) |
| CFO/TA -0.04 > 3% & CFO -18.2m > Net Income -7.42m |
| Net Debt (99.0m) to EBITDA (77.2m): 1.28 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (251.4m) vs 12m ago 28.16% < -2% |
| Gross Margin: 65.00% > 18% (prev 0.65%; Δ 6.43k% > 0.5%) |
| Asset Turnover: 106.3% > 50% (prev 80.11%; Δ 26.24% > 0%) |
| Interest Coverage Ratio: 1.70 > 6 (EBITDA TTM 77.2m / Interest Expense TTM 45.4m) |
| A: 0.34 (Total Current Assets 459.5m - Total Current Liabilities 300.4m) / Total Assets 462.5m |
| B: -3.56 (Retained Earnings -1.65b / Total Assets 462.5m) |
| C: 0.20 (EBIT TTM 77.1m / Avg Total Assets 393.3m) |
| D: -2.14 (Book Value of Equity -1.65b / Total Liabilities 770.5m) |
| Altman-Z'' = -10.30 = D |
| DSRI: 1.01 (Receivables 132.4m/81.3m, Revenue 418.2m/259.6m) |
| GMI: 1.00 (GM 65.00% / 65.30%) |
| AQI: 0.70 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.61 (Revenue 418.2m / 259.6m) |
| TATA: 0.02 (NI -7.42m - CFO -18.2m) / TA 462.5m) |
| Beneish M = -2.73 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 3.13 with a total of 5,074,442 shares traded.
Over the past week, the price has changed by +0.00%,
over one month by +63.87%,
over three months by -6.57% and
over the past year by +259.52%.
Esperion Therapeutics has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold ESPR.
- StrongBuy: 2
- Buy: 2
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 3.2 | 1.9% |
P/E Forward = 4.6382
P/S = 1.9204
P/B = 98.4236
P/EG = -4.78
Revenue TTM = 418.2m USD
EBIT TTM = 77.1m USD
EBITDA TTM = 77.2m USD
Long Term Debt = 250.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.70m USD (from shortTermDebt, last quarter)
Debt = 255.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.56m
Net Debt = 99.0m USD (calculated: Debt 255.2m - CCE 156.2m)
Enterprise Value = 902.2m USD (803.2m + Debt 255.2m - CCE 156.2m)
Interest Coverage Ratio = 1.70 (Ebit TTM 77.1m / Interest Expense TTM 45.4m)
EV/FCF = -49.61x (Enterprise Value 902.2m / FCF TTM -18.2m)
FCF Yield = -2.02% (FCF TTM -18.2m / Enterprise Value 902.2m)
FCF Margin = -4.35% (FCF TTM -18.2m / Revenue TTM 418.2m)
Net Margin = -1.77% (Net Income TTM -7.42m / Revenue TTM 418.2m)
Gross Margin = 65.00% ((Revenue TTM 418.2m - Cost of Revenue TTM 146.4m) / Revenue TTM)
Gross Margin QoQ = 56.84% (prev 83.46%)
Tobins Q-Ratio = 1.95 (Enterprise Value 902.2m / Total Assets 462.5m)
Interest Expense / Debt = 17.78% (Interest Expense 45.4m / Debt 255.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 60.9m (EBIT 77.1m * (1 - 21.00%))
Current Ratio = 1.53 (Total Current Assets 459.5m / Total Current Liabilities 300.4m)
Debt / Equity = -0.83 (negative equity) (Debt 255.2m / totalStockholderEquity, last quarter -307.9m)
Debt / EBITDA = 1.28 (Net Debt 99.0m / EBITDA 77.2m)
Debt / FCF = -5.45 (negative FCF - burning cash) (Net Debt 99.0m / FCF TTM -18.2m)
Total Stockholder Equity = -373.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.89% (Net Income -7.42m / Total Assets 462.5m)
RoE = -0.58% (Net Income TTM -7.42m / Total Stockholder Equity 1.28b)
RoCE = 5.05% (EBIT 77.1m / Capital Employed (Equity 1.28b + L.T.Debt 250.1m))
RoIC = 42.94% (NOPAT 60.9m / Invested Capital 141.8m)
WACC = 14.27% (E(803.2m)/V(1.06b) * Re(14.34%) + D(255.2m)/V(1.06b) * Rd(17.78%) * (1-Tc(0.21)))
Discount Rate = 14.34% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 43.00%
[DCF] Fair Price = unknown (Cash Flow -18.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.68 | # QB: 0
Revenue Correlation: 88.12 | Revenue CAGR: 67.43% | SUE: -0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.07 | Chg30d=N/A | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.04 | Chg30d=N/A | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.21 | Chg30d=N/A | Revisions=+20% | GrowthEPS=-90.9% | GrowthRev=-16.3%
EPS next Year (2027-12-31): EPS=0.29 | Chg30d=-0.44% | Revisions=N/A | GrowthEPS=+239.0% | GrowthRev=+35.3%
[Analyst] Revisions Ratio: +20%